PARSIPPANY, N.J. (AP) — Watson Pharmaceuticals Inc. said Monday it received approval to sell a generic version of Pfizer Inc.'s drug Revatio, a treatment for pulmonary arterial hypertension.
Watson said it will bring its generic to market soon. It said U.S. sales of Revatio totaled $339 million over the 12 months ended Sept. 30. The drug treats high blood pressure in lung arteries.
The main ingredient in Revatio is sildenafil citrate. That's also the main component of Pfizer's blockbuster impotence pill Viagra, which was originally developed to treat blood pressure problems. Viagra tablets contain larger doses of the drug than Revatio, and generic versions of Viagra are not expected to reach the market until late 2019.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
- Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
- Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
Already have an account? Sign In
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
